I have ordered a 2400-bp nucleotide fragment (codon-optimized for Lactococcus lactis), to be synthesized and cloned in E. coli by a commercial firm. The company has now informed me that they were unable to produce the fragment in correct ORF, due to formation of a few disruptive point mutations. I was wondering:
1- Are these mutations happening because the sequence is toxic to E. coli?
2- How can I circumvent this problem?
3- Can removing the area where these point mutations have happened, solve this problem?
With many thanks in advance for your inputs,
Edited by IPI, 10 May 2013 - 08:52 PM.